ADHD Medication in the UK: What You Need to Know

A Clear Starting Point

If you have recently been diagnosed with ADHD, medication may feel hopeful, worrying, or both. Online discussions can make the process sound much more certain than it really is. One person says Elvanse changed everything. Another says methylphenidate was better. A third gives a dose or switching schedule that may be completely wrong for your medicine and health.

The reliable starting point is simpler: ADHD medication is individual treatment that must be initiated and monitored by a healthcare professional with training and expertise in ADHD.

I am an ADHD mentor and social worker, not a prescribing clinician. This guide is general information, not a recommendation or personal medical advice. I source checked it against current NICE guideline NG87, NHS information and UK medicine safety guidance on 29 July 2026. It has not been clinically reviewed.

If you are still seeking an assessment, read the guide to getting an ADHD diagnosis in the UK first.

Which ADHD Medicines Does NICE Recommend for Adults?

NICE sets out a sequence for adult medication. It is not a league table and it does not predict which medicine will suit you.

NICE recommends lisdexamfetamine or methylphenidate as first-line pharmacological treatment for adults. Claims that methylphenidate is always first-line, or that Elvanse is always first-line, are both inaccurate.

The exact product matters. Methylphenidate is sold in immediate-release and modified-release formulations with different release patterns and food instructions. If you are comparing options, read:

• Ritalin versus Elvanse for immediate-release methylphenidate versus long-acting lisdexamfetamine
• Concerta XL versus Elvanse for two long-acting options

Do not compare dose numbers across different active ingredients. Milligrams of one medicine are not equivalent to the same number of milligrams of another.

Who Starts and Prescribes ADHD Medication?

NICE says all ADHD medication should be initiated by a healthcare professional with training and expertise in diagnosing and managing ADHD.

After titration and dose stabilisation, NICE recommends prescribing and monitoring under a shared-care protocol with primary care. In practice, a shared-care transfer still requires agreement. The clinician signing a prescription remains responsible for it, and local commissioning and prescribing policies can affect what a GP practice accepts.

This means:

• a specialist or other appropriately trained ADHD clinician usually initiates and titrates treatment
• the specialist should provide a clear treatment and monitoring plan
• a GP may take over agreed elements after stabilisation
• shared care is not automatic, including after an NHS, Right to Choose or private assessment
• if shared care is declined, ask who will continue prescribing and monitoring before your current supply runs out

My shared-care agreement guide explains the process in more detail, but time-sensitive local rules should always be checked with the provider, GP and local NHS body.

Checks Before Medication Starts

NICE recommends a full baseline assessment before medication. This includes:

• confirming that ADHD criteria and the need for treatment still apply
• reviewing mental health, social circumstances, other neurodevelopmental conditions and substance-use or diversion risk
• reviewing medical history and current medicines
• measuring height and weight
• measuring pulse and blood pressure
• completing a cardiovascular assessment

A routine ECG is not required for everyone before stimulants, atomoxetine or guanfacine. NICE recommends an ECG or cardiology opinion when specific clinical features, cardiovascular history or another medicine create increased risk.

Tell the initiating clinician about all prescribed medicines, over-the-counter products and supplements. Also disclose alcohol or substance use honestly. This is safety information, not a moral test.

What Titration Actually Means

Titration is the supervised process of adjusting treatment until there is a useful reduction in symptoms and impairment with tolerable adverse effects.

NICE says symptoms, impairment and adverse effects should be recorded at baseline and at each dose change, with progress reviewed regularly, for example through weekly specialist contact. Titration should be slower and monitoring more frequent for some coexisting neurodevelopmental, mental health or physical conditions.

There is no single four-week, six-week or eight-week promise that applies to everyone. The time needed depends on the medicine, response, adverse effects, missed appointments, monitoring and whether another option needs to be tried.

A simple record can make reviews more useful:

• exact medicine, formulation, dose and time taken
• when you first notice benefit and when it seems to end
• changes in attention, impulsivity and task initiation
• effects on work, study, relationships and daily responsibilities
• sleep, appetite, weight concerns and mood
• any adverse effect or safety concern

Do not increase, reduce, split, skip or combine doses unless your prescriber has told you to do so.

Side Effects and Ongoing Monitoring

Side effects differ between medicines and people. Commonly discussed stimulant effects include reduced appetite, sleep difficulty, headache, dry mouth, and changes in heart rate or blood pressure. Atomoxetine and guanfacine have different profiles and their own important warnings.

Read the patient leaflet supplied with your exact product. Contact your prescriber or pharmacist about side effects that concern you, and use urgent services for severe or life-threatening symptoms.

For adults taking ADHD medication, NICE recommends:

• recording effectiveness and adverse effects
• measuring weight every six months
• monitoring heart rate and blood pressure before and after each dose change and every six months
• monitoring sleep changes and adjusting treatment with the clinician when needed
• a medication review at least once a year by a professional with ADHD expertise

NICE does not recommend routine blood tests or ECGs unless there is a clinical reason.

The yearly review should consider benefits, adverse effects, whether treatment is optimised, effects of missed doses, and the person's preferences. It may include a discussion about a supervised trial reduction or stopping, but this is not something to attempt without clinical guidance.

Alcohol, Driving and Other Safety Questions

Advice about alcohol differs by medicine. The ADHD medication and alcohol guide explains the current UK wording for methylphenidate, Elvanse, atomoxetine and guanfacine. Ask your prescriber or pharmacist about your exact product rather than relying on a general rule.

ADHD and its medicines can also affect driving. You must tell the DVLA if ADHD, medication or both affect your ability to drive safely. Do not drive until you know how a new medicine or dose affects you, and follow the warning in the patient leaflet.

Medicine Availability and Brand Changes

Supply can change by product, strength and region. Avoid evergreen claims that every ADHD medicine is in shortage or that supply has fully recovered.

If your pharmacy cannot obtain the prescribed product:

1. Ask the pharmacist what is unavailable and whether the issue is local or wider.
2. Contact the prescriber before changing strength, formulation or brand.
3. Do not combine tablets or capsules into a substitute dose unless the prescriber or pharmacist confirms the exact plan.
4. Order within the timeframe your controlled-drug prescription allows and avoid leaving the request until the last dose.

Long-acting methylphenidate products are not automatically interchangeable. The MHRA warns that they can differ in dosing frequency, food instructions, modified-release proportion and clinical effect.

The separate ADHD medication shortage guide covers practical steps, but check its update date and current official supply information each time you use it.

Medication and Non-Clinical Support

Medication can reduce ADHD symptoms and impairment, but it does not automatically create a planning system, repair an overloaded calendar or decide which commitments matter.

NICE recommends considering non-pharmacological treatment alongside medication for adults who have benefited from medication but still have significant impairment in at least one area. The minimum NICE recommendation in that clinical context is a structured supportive psychological intervention focused on ADHD with regular follow-up, potentially including CBT.

ADHD mentoring is not a substitute for that clinical intervention. It is non-clinical support for practical goals such as:

• building routines and external reminders
• planning work, study or household tasks
• understanding patterns around time, energy and overwhelm
• creating accountability for chosen actions
• preparing observations and questions for a clinical review without interpreting them medically

If You Are Unsure About Medication

It is reasonable to have questions or to choose not to take medication. NICE recommends medication for adults whose ADHD symptoms still cause significant impairment after environmental modifications have been implemented and reviewed. It also recommends considering non-pharmacological treatment when an adult makes an informed choice not to have medication, cannot adhere to it, or finds it ineffective or intolerable.

Discuss benefits, risks and alternatives with a qualified ADHD clinician. If you are waiting for diagnosis or treatment, the guide to coping on an NHS ADHD waiting list offers practical non-clinical steps.

If you want help with day-to-day ADHD strategies, you can review my ADHD mentoring services. Mentoring will not tell you whether to start, stop or change medication.

Sources and Further Reading

• NICE NG87: attention deficit hyperactivity disorder, diagnosis and management
• NHS: ADHD in adults
• NHS: methylphenidate for adults
• MHRA advice on switching modified-release methylphenidate products